Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bio-Reference Labs. Posts Lower Q1 Profit - Quick Facts

RELATED NEWS
Trade BRLI now with 

Bio-Reference Laboratories Inc.'s (BRLI: Quote) first-quarter net income decreased to $7.36 million or $0.26 per share from $7.99 million or $0.28 per share last year.

The company recorded quarterly revenues of $149.92 million, a 23% increase over $121.66 million reported in the prior-year quarter.

On average, 5 analysts polled by Thomson Reuters expected earnings per share of $0.21 on $143.13 million revenue for the quarter. Analysts' estimates typically exclude one-time items.

Marc Grodman, MD, CEO, commented: "The milder than normal weather conditions, particularly in the Northeast, have contributed to the strength of our Q1 results when compared to our prior year results. However, and more importantly, the overall success of all our business units has been the primary reason for our strong financial results."

Click here to receive FREE breaking news email alerts for Bio Reference Laboratories Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved sharply lower over the course of the trading day on Wednesday, adding to the modest weakness seen in the two previous sessions. With the losses on the day, the major averages fell to their lowest closing levels in over a month. Democrats have climbed into the lead on a generic ballot, according to the results of a new CNN/ORC International poll, although the results may not be as positive for the party as they first appear. With spending on private and public construction both showing notable decreases, the Commerce Department released a report on Wednesday showing an unexpected drop in U.S. construction spending in the month of August.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.